<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="197">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988026</url>
  </required_header>
  <id_info>
    <org_study_id>MXMIN-001</org_study_id>
    <nct_id>NCT00988026</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatment of Mild to Moderate Acne</brief_title>
  <acronym>MXMIN-001</acronym>
  <official_title>Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Darier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Darier</source>
  <oversight_info>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial to compare the benefits and possible adverse events of two
      antibiotic treatments for mild to moderate acne.  It is expected that minocycline
      microgranules will be more effective than lymecycline   with a better adverse events
      profile.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of inflammatory and non-inflammatory acne lesions</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of local and systemic adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Mild to Moderate Acne</condition>
  <arm_group>
    <arm_group_label>Minocycline 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymecycline 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: Lymecycline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline vs Lymecycline</intervention_name>
    <description>Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.</description>
    <arm_group_label>Minocycline 100 mg</arm_group_label>
    <arm_group_label>Lymecycline 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both gender

          -  14 to 30 years old

          -  Mild to moderate acne

          -  Face localization

          -  At least 20 non-inflammatory lesions OR

          -  At least 15 inflammatory lesions OR

          -  At least 30 total lesions AND

          -  Less than 5 nodular lesions

        Exclusion Criteria:

          -  Patients younger than 14 or older than 30 years old

          -  Less than  20 non-inflammatory lesions OR

          -  Less than 15 inflammatory lesions OR

          -  Less than 30 total lesions

          -  Patients with severe acne

          -  More than 5 nodular lesions OR

          -  More than 50 inflammatory lesions OR

          -  More than 125 total lesions

          -  Pregnant women

          -  Lactating women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luis Leobardo Velázquez-Arenas, MD</last_name>
    <phone>(5281)83481465</phone>
    <email>leovel2002@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jorge Ocampo-Candiani, MD</last_name>
    <phone>(5281)83481465</phone>
    <email>jocampo2000@yahoo.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Servicio de Dermatología. Hospital &quot; Dr. José Eleuterio González&quot; de la Universidad Autónoma de Nuevo León</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Ojeda-Martínez, RN</last_name>
      <phone>(5281)83481465</phone>
      <email>blanca_ojeda21@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <lastchanged_date>September 30, 2009</lastchanged_date>
  <firstreceived_date>September 30, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Luis Leobardo Velázquez-Arenas</name_title>
    <organization>Hospital &quot;Dr. José Eleuterio González&quot; de la Universidad Autónoma de Nuevo Léon</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymecycline</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
